[
  {
    "ts": null,
    "headline": "Incyte (INCY) Stock Is Up, What You Need To Know",
    "summary": "Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 2.4% in the afternoon session after Barclays initiated coverage on the stock with an Overweight rating, helping the shares reach a new 52-week high. The investment bank noted a \"compelling inflection point\" for the biotechnology firm, highlighting multiple maturing assets that could drive future revenue growth. Further bolstering investor confidence, RBC Capital raised its price target on Incyte to $72, citing strong dem",
    "url": "https://finnhub.io/api/news?id=17fb693c41db703b12d5dc06d8d3206318183667d870449a54faa430271e517c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756845338,
      "headline": "Incyte (INCY) Stock Is Up, What You Need To Know",
      "id": 136613754,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 2.4% in the afternoon session after Barclays initiated coverage on the stock with an Overweight rating, helping the shares reach a new 52-week high. The investment bank noted a \"compelling inflection point\" for the biotechnology firm, highlighting multiple maturing assets that could drive future revenue growth. Further bolstering investor confidence, RBC Capital raised its price target on Incyte to $72, citing strong dem",
      "url": "https://finnhub.io/api/news?id=17fb693c41db703b12d5dc06d8d3206318183667d870449a54faa430271e517c"
    }
  }
]